nnmti

NNMTi (5-Amino-1-methylquinolinium) is a substrate site-targeting, selective nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 1.2 μM; 50 μM SAM, 100 μM NCA) that reduces 3T3-L1 lipogenesis (EC50 = 30μM) and adipocytes 1-methylnicotinamide level (EC50 = 2.3 μM) without affecting related methyltransferases & enzymes in the NAD+ salvage pathway

NNMT-IN-7 (Compound 4e) is an NNMT inhibitor with an IC50 of 505.7 µM. It is useful for research in metabolic and chronic diseases.

NNMT-IN-6 hydrochloride (compound 78) is a potent inhibitor of nicotinamide N-methyltransferase (NNMT), exhibiting an IC50 of 1.41 μM and a Kd of 5.6 μM. It effectively suppresses the proliferation of HSC-2 human oral cancer cell lines.

NNMT-IN-5 (Compound 3-12) is a potent inhibitor of nicotinamide N-methyltransferase (NNMT) with an IC50 value of 47.9 ± 0.6 nM. This compound exhibits exceptional selectivity for a set of human methyltransferases. NNMT-IN-5 is applicable in research related to cancer, diabetes, metabolic disorders, and neurodegenerative diseases.

NNMT-IN-3 (compound 14) is a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT), with IC50 values of 1.1 nM in cell-free assays and 0.4 μM in cell-based assays. NNMT-IN-3 can be utilized in studies of obesity, cancer, type II diabetes, and skeletal sarcopenia, among other diseases.

NNMT-IN-4 (compound 38) is a selective, uncompetitive inhibitor of nicotinamide N-methyltransferase (NNMT) with in vitro biochemical and cell-based assay IC50 values of 42 nM and 38 nM, respectively. It demonstrates favorable pharmacokinetics/pharmacodynamics (PK/PD) and safety profiles, excellent oral bioavailability, and promising pharmaceutical properties. NNMT-IN-4 serves as an in vivo chemical probe for NNMT [1].